In early 2005, a unique gain-of-function mutation in the Janus kinase 2 gene (JAK2V617F) was identified in approximately 95% of patients with PV and in 50% to 60% of patients with ET or PMF [1,2]. This evidence concerns the gene JAK2 and essential thrombocythemia.